

# Ya-Chen Tina Shih

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1096154/publications.pdf>

Version: 2024-02-01

118  
papers

6,911  
citations

186265

28  
h-index

62596

80  
g-index

122  
all docs

122  
docs citations

122  
times ranked

9734  
citing authors

#	ARTICLE	IF	CITATIONS
1	Statistical modeling of longitudinal medical cost trajectory: renal cell cancer care cost analyses. <i>Biostatistics</i> , 2023, 24, 244-261.	1.5	3
2	Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2022, 114, 254-262.	6.3	16
3	Treating the Whole Patient With Cancer: The Critical Importance of Understanding and Addressing the Trajectory of Medical Financial Hardship. <i>Journal of the National Cancer Institute</i> , 2022, , .	6.3	7
4	Health Economics Research in Cancer Screening: Research Opportunities, Challenges, and Future Directions. <i>Journal of the National Cancer Institute Monographs</i> , 2022, 2022, 42-50.	2.1	7
5	Smoking cessation services and shared decision-making practices among lung cancer screening facilities: A cross-sectional study. <i>Cancer</i> , 2022, 128, 1967-1975.	4.1	2
6	Cancer's Lasting Financial Burden: Evidence From a Longitudinal Assessment. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1020-1028.	6.3	8
7	Comparison of an automated smartphone-based smoking cessation intervention versus standard quitline-delivered treatment among underserved smokers: protocol for a randomized controlled trial. <i>BMC Public Health</i> , 2022, 22, 563.	2.9	3
8	Financial toxicity impact on younger versus older adults with cancer in the setting of care delivery. <i>Cancer</i> , 2022, 128, 2455-2462.	4.1	13
9	Global Challenges in Access to and Implementation of Precision Oncology: The Health Care Manager and Health Economist Perspective. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 429-437.	3.8	3
10	Time to add screening for financial hardship as a quality measure?. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 100-106.	329.8	26
11	A framework for cancer health economics research. <i>Cancer</i> , 2021, 127, 994-996.	4.1	5
12	Smoking cessation and shared decision-making practices about lung cancer screening among primary care providers. <i>Cancer Medicine</i> , 2021, 10, 1357-1365.	2.8	6
13	Implementation of Shared Decision Making for Lung Cancer Screening Among the Privately Insured Nonelderly. <i>MDM Policy and Practice</i> , 2021, 6, 238146832098477.	0.9	3
14	Improving the Process of Screening for Medical Financial Hardship in Oncology Practice. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 593-596.	2.5	14
15	Reply to M. K. Kirkwood et al. <i>JCO Oncology Practice</i> , 2021, 17, 296-297.	2.9	0
16	Sensitivity of Psychosocial Distress Screening to Identify Cancer Patients at Risk for Financial Hardship During Care Delivery. <i>JCO Oncology Practice</i> , 2021, 17, e1856-e1865.	2.9	10
17	Incorporating Baseline Breast Density When Screening Women at Average Risk for Breast Cancer. <i>Annals of Internal Medicine</i> , 2021, 174, 602-612.	3.9	6
18	Financial Burden of Discarded Weight-based Antineoplastic Drugs to Payers and Patients in the Private Insurance Market. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab045.	2.9	3

#	ARTICLE	IF	CITATIONS
19	Financial Toxicity in Head and Neck Cancer Patients Treated With Proton Therapy. <i>International Journal of Particle Therapy</i> , 2021, 8, 366-373.	1.8	6
20	Increased Incidence of Human Papillomavirus-Related Precancer or Second Malignancy Among Allogeneic Stem Cell Transplantation Patients: A SEER-Medicare Population Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 1016.e1-1016.e9.	1.2	1
21	A Systematic Review of Economic and Quality-of-Life Research in Carcinoid Syndrome. <i>Pharmacoeconomics</i> , 2021, 39, 1271-1297.	3.3	2
22	Evaluating the Efficacy of Automated Smoking Treatment for People With HIV: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e33183.	1.0	0
23	A look at the gynecologic oncologist workforce – Are we meeting patient demand?. <i>Gynecologic Oncology</i> , 2021, 163, 229-236.	1.4	8
24	Financial Hardship in Survivorship Care Delivery. <i>Journal of the National Cancer Institute Monographs</i> , 2021, 2021, 10-14.	2.1	11
25	Exploring racial and ethnic disparities in medication adherence among Medicare comprehensive medication review recipients. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 3, 100041.	1.0	2
26	State of Physician and Pharmacist Oncology Workforce in the United States in 2019. <i>JCO Oncology Practice</i> , 2021, 17, e1-e10.	2.9	14
27	Addressing Cancer Financial Hardship Begins With Comprehensive Assessment of Patient Economic Burden. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1606-1607.	6.3	1
28	A Coordinated Policy Approach to Address Medical Financial Toxicity. <i>JAMA Oncology</i> , 2021, 7, 1761.	7.1	6
29	Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective. <i>Journal of the National Cancer Institute</i> , 2021, 113, 660-661.	6.3	2
30	Evaluation of the Efficacy of a Smoking Cessation Intervention for Cervical Cancer Survivors and Women With High-Grade Cervical Dysplasia: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e34502.	1.0	3
31	Time to Consider a Personalized Approach to Incorporate Tomosynthesis Into Routine Breast Cancer Screening. <i>Journal of the National Cancer Institute</i> , 2020, 112, 553-554.	6.3	1
32	Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation. <i>Journal of Clinical Oncology</i> , 2020, 38, 292-301.	1.6	80
33	Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 321-346.	329.8	481
34	Choice of local therapy for young women with early-stage breast cancer who have young-aged children. <i>Cancer</i> , 2020, 126, 4761-4769.	4.1	0
35	Updated Analysis of Complication Rates Associated With Invasive Diagnostic Procedures After Lung Cancer Screening. <i>JAMA Network Open</i> , 2020, 3, e2029874.	5.9	15
36	Rising Economic Burden of Renal Cell Carcinoma among Elderly Patients in the USA: Part II – An Updated Analysis of SEER-Medicare Data. <i>Pharmacoeconomics</i> , 2019, 37, 1495-1507.	3.3	16

#	ARTICLE	IF	CITATIONS
37	Use of Claims Data for Cost and Cost-Effectiveness Research. <i>Seminars in Radiation Oncology</i> , 2019, 29, 348-353.	2.2	10
38	Cardiovascular health in young and middle adulthood and medical care utilization and costs at older age – The Chicago Heart Association Detection Project Industry (CHA). <i>Preventive Medicine</i> , 2019, 119, 87-98.	3.4	8
39	Smoking Cessation Treatment Needs of Low SES Cervical Cancer Survivors. <i>American Journal of Health Behavior</i> , 2019, 43, 606-620.	1.4	10
40	Assessing the Cost-Effectiveness of Updated Breast Cancer Screening Guidelines for Average-Risk Women. <i>Value in Health</i> , 2019, 22, 185-193.	0.3	16
41	Economic Burden of Renal Cell Carcinoma – Part I: An Updated Review. <i>Pharmacoeconomics</i> , 2019, 37, 301-331.	3.3	25
42	Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful Use. <i>Value in Health</i> , 2018, 21, 334-340.	0.3	32
43	Price Transparency for Whom? In Search of Out-of-Pocket Cost Estimates to Facilitate Cost Communication in Cancer Care. <i>Pharmacoeconomics</i> , 2018, 36, 259-261.	3.3	23
44	Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1094-1098.	2.0	11
45	State insurance mandates and off-label use of chemotherapy. <i>Health Economics (United Kingdom)</i> , 2018, 27, e55-e70.	1.7	8
46	Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia. <i>Cancer</i> , 2018, 124, 364-373.	4.1	31
47	Semiparametric Estimation of Longitudinal Medical Cost Trajectory. <i>Journal of the American Statistical Association</i> , 2018, 113, 582-592.	3.1	10
48	Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1823-1830.	1.6	70
49	Predictive value positive of MTM eligibility criteria under MMA and ACA in identifying individuals with medication utilization issues. <i>Journal of Pharmaceutical Health Services Research</i> , 2018, 9, 393-401.	0.6	1
50	Racial and Ethnic Disparities in Meeting MTM Eligibility Criteria Based on Star Ratings Compared with the Medicare Modernization Act. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 97-107.	0.9	6
51	Insurance transitions and healthcare utilization for children with refractory epilepsy. <i>Epilepsy and Behavior</i> , 2018, 89, 48-54.	1.7	4
52	Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 250-281.	329.8	1,287
53	Use of CT and Chest Radiography for Lung Cancer Screening Before and After Publication of Screening Guidelines. <i>JAMA Internal Medicine</i> , 2017, 177, 439.	5.1	105
54	Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. <i>Lancet Oncology</i> , The, 2017, 18, 525-534.	10.7	271

#	ARTICLE	IF	CITATIONS
55	Favorable Cardiovascular Health, Compression of Morbidity, and Healthcare Costs. <i>Circulation</i> , 2017, 135, 1693-1701.	1.6	57
56	Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis. <i>Pharmacoeconomics</i> , 2017, 35, 685-695.	3.3	7
57	A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment. <i>Cancer</i> , 2017, 123, 928-939.	4.1	106
58	Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients. <i>Oncologist</i> , 2017, 22, 1451-1462.	3.7	20
59	Do Robotic Surgical Systems Improve Profit Margins? A Cross-Sectional Analysis of California Hospitals. <i>Value in Health</i> , 2017, 20, 1221-1225.	0.3	4
60	Combined treatment for at-risk drinking and smoking cessation among Puerto Ricans: A randomized clinical trial. <i>Addictive Behaviors</i> , 2017, 65, 185-192.	3.0	20
61	Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries. <i>Journal of Clinical Oncology</i> , 2017, 35, 2482-2489.	1.6	82
62	Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications. <i>Journal of Oncology Practice</i> , 2017, 13, e152-e162.	2.5	21
63	Cost-Effectiveness Analysis of a Capitated Patient Navigation Program for Medicare Beneficiaries with Lung Cancer. <i>Health Services Research</i> , 2016, 51, 746-767.	2.0	14
64	Post-mastectomy breast reconstruction and its subsequent complications: a comparison between obese and non-obese women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 373-383.	2.5	19
65	A comparison of patient-centered economic and clinical outcomes of post-mastectomy breast reconstruction between obese and non-obese patients. <i>Breast</i> , 2016, 30, 118-124.	2.2	19
66	A flexible model for correlated medical costs, with application to medical expenditure panel survey data. <i>Statistics in Medicine</i> , 2016, 35, 883-894.	1.6	17
67	Potential Health Implications of Medication Therapy Management Eligibility Criteria in the Patient Protection and Affordable Care Act Across Racial and Ethnic Groups. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2015, 21, 993-1003.	0.9	9
68	Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. <i>Journal of Clinical Oncology</i> , 2015, 33, 2190-2196.	1.6	132
69	Predicting the EQ-5D-3L Preference Index from the SF-12 Health Survey in a National US Sample. <i>Medical Decision Making</i> , 2015, 35, 888-901.	2.4	19
70	In Reply to Rusthoven and Kavanagh. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 680-681.	0.8	0
71	Treatment Patterns and Costs for Metastatic Renal Cell Carcinoma Patients With Private Insurance in the United States. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e93-e100.	1.9	32
72	The Association between Patient-Centered Attributes of Care and Patient Satisfaction. <i>Patient</i> , 2015, 8, 187-197.	2.7	13

#	ARTICLE	IF	CITATIONS
73	Breast Cancer Screening for Women at Average Risk. JAMA - Journal of the American Medical Association, 2015, 314, 1599.	7.4	1,283
74	Trends in Medicare Part D Medication Therapy Management Eligibility Criteria. American Health and Drug Benefits, 2015, 8, 247-55.	0.5	8
75	Preparing for an Epidemic: Cancer Care in an Aging Population. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 133-137.	3.8	17
76	Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review. Human Vaccines and Immunotherapeutics, 2014, 10, 3415-3424.	3.3	39
77	Potential effects of racial and ethnic disparities in meeting Medicare medication therapy management eligibility criteria. Journal of Pharmaceutical Health Services Research, 2014, 5, 109-118.	0.6	5
78	A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 45-69.	1.4	15
79	Geographic Variation in Radiologist Capacity and Widespread Implementation of Lung Cancer CT Screening. Journal of Medical Screening, 2014, 21, 207-215.	2.3	21
80	Factors Contributing to Underuse of Radiation Among Younger Women With Breast Cancer. Journal of the National Cancer Institute, 2014, 106, djt340-djt340.	6.3	38
81	The cost-effectiveness of a trial of labor accrues with multiple subsequent vaginal deliveries. American Journal of Obstetrics and Gynecology, 2014, 211, 56.e1-56.e12.	1.3	19
82	First do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer. Breast Cancer Research and Treatment, 2014, 144, 417-425.	2.5	7
83	Considerations for Observational Research Using Large Data Sets in Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2014, 90, 11-24.	0.8	70
84	Comparative Effectiveness of Robot-assisted Versus Open Radical Prostatectomy Cancer Control. European Urology, 2014, 66, 666-672.	1.9	97
85	The Role of Economic Evaluation in Meeting IOM's Recommendations on Delivering High-Quality Cancer Care. Value in Health, 2014, 17, 497-500.	0.3	4
86	Effects of medicare part d on disparity implications of medication therapy management eligibility criteria. American Health and Drug Benefits, 2014, 7, 346-58.	0.5	4
87	The role of statins for primary prevention in non-elderly colorectal cancer patients. Anticancer Research, 2014, 34, 5043-50.	1.1	10
88	American Cancer Society lung cancer screening guidelines. Ca-A Cancer Journal for Clinicians, 2013, 63, 106-117.	329.8	611
89	Practice-Changing Strategies to Deliver Affordable, High-Quality Cancer Care: Summary of an Institute of Medicine Workshop. Journal of Oncology Practice, 2013, 9, 54s-59s.	2.5	7
90	Delivering High-Quality and Affordable Care Throughout the Cancer Care Continuum. Journal of Clinical Oncology, 2013, 31, 4151-4157.	1.6	62

#	ARTICLE	IF	CITATIONS
91	A flexible model for the mean and variance functions, with application to medical cost data. <i>Statistics in Medicine</i> , 2013, 32, 4306-4318.	1.6	16
92	Use of Radiation Therapy in the Last 30 Days of Life Among a Large Population-Based Cohort of Elderly Patients in the United States. <i>Journal of Clinical Oncology</i> , 2013, 31, 80-87.	1.6	133
93	Reconciling Cancer Care Costs Reported by Different Government Agencies in Taiwan: Why Costing Approach Matters?. <i>Value in Health Regional Issues</i> , 2012, 1, 111-117.	1.2	2
94	Comparative Effectiveness, Cost, and Utilization of Radical Prostatectomy among Young Men within Managed Care Insurance Plans. <i>Value in Health</i> , 2012, 15, 367-375.	0.3	8
95	Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC). <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 201.	1.9	10
96	Physicians' perception of demand-induced supply in the information age: a latent class model analysis. <i>Health Economics (United Kingdom)</i> , 2012, 21, 252-269.	1.7	23
97	Economic Burden of Renal Cell Carcinoma. <i>Pharmacoeconomics</i> , 2011, 29, 315-329.	3.3	16
98	Economic Burden of Renal Cell Carcinoma in the US. <i>Pharmacoeconomics</i> , 2011, 29, 331-341.	3.3	19
99	Disparity Implications of Medicare Eligibility Criteria for Medication Therapy Management Services. <i>Health Services Research</i> , 2010, 45, 1061-1082.	2.0	36
100	Immunotherapy in the Initial Treatment of Newly Diagnosed Cancer Patients: Utilization Trend and Cost Projections for Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Metastatic Colorectal Cancer. <i>Cancer Investigation</i> , 2010, 28, 46-53.	1.3	15
101	Cost-Utility Analysis of Palonosetron-Based Therapy in Preventing Emesis Among Breast Cancer Patients. <i>The Journal of Supportive Oncology</i> , 2010, 8, 242-251.	2.3	18
102	Influenza Vaccination Among Individuals with Cancer and Their Family Members. <i>American Journal of Preventive Medicine</i> , 2010, 38, 61-69.	3.0	54
103	Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 2007-2014.	1.6	378
104	Information Technology Facilitates Cost-Effectiveness Analysis in Developing Countries. <i>Pharmacoeconomics</i> , 2009, 27, 947-961.	3.3	16
105	Factors Associated With Immunotherapy Use Among Newly Diagnosed Cancer Patients. <i>Medical Care</i> , 2009, 47, 948-958.	2.4	23
106	Disparities in Colorectal Screening Between US-Born and Foreign-Born Populations: Evidence from the 2000 National Health Interview Survey. <i>Journal of Cancer Education</i> , 2008, 23, 18-25.	1.3	39
107	Economic Evaluations of Medical Care Interventions for Cancer Patients: How, Why, and What Does it Mean?. <i>Ca-A Cancer Journal for Clinicians</i> , 2008, 58, 231-244.	329.8	76
108	Use of Bayesian Net Benefit Regression Model to Examine the Impact of Generic Drug Entry on the Cost Effectiveness of Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients. <i>Pharmacoeconomics</i> , 2007, 25, 843-862.	3.3	14

#	ARTICLE	IF	CITATIONS
109	Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy. <i>Cancer</i> , 2007, 110, 678-685.	4.1	88
110	Factors Associated with the Income Distribution of Full-Time Physicians: A Quantile Regression Approach. <i>Health Services Research</i> , 2007, 42, 1895-1925.	2.0	21
111	Do Pharmacogenomic Tests Provide Value to Policy Makers?. <i>Pharmacoeconomics</i> , 2006, 24, 1173-1177.	3.3	3
112	The Association between Symptom Burdens and Utility in Chinese Cancer Patients. <i>Quality of Life Research</i> , 2006, 15, 1427-1438.	3.1	11
113	Does Medicare Coverage Of Colonoscopy Reduce Racial/Ethnic Disparities In Cancer Screening Among the Elderly?. <i>Health Affairs</i> , 2006, 25, 1153-1162.	5.2	81
114	Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. <i>Kidney International</i> , 2005, 68, 319-329.	5.2	104
115	Impact of Generic Drug Entry on Cost-Effectiveness Analysis. <i>Medical Decision Making</i> , 2005, 25, 71-80.	2.4	28
116	Health care provider knowledge of drug formulary status in ambulatory care settings. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 2657-2663.	1.0	10
117	Bayesian approach in pharmacoeconomics: relevance to decision-makers. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2003, 3, 237-250.	1.4	8
118	Impact of race-specific screening guideline on the uptake of colorectal cancer screening among young African Americans. <i>Cancer Medicine</i> , 0, , .	2.8	1